Kyowa Kirin Co ((KYKOF)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Kyowa Kirin Co. is conducting a Phase 2 clinical study titled ‘A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema.’ The study aims to evaluate the efficacy and safety of KHK4951 eye drops in treating Diabetic Macular Edema (DME), a condition that can lead to vision loss in diabetic patients.
The study tests the intervention of KHK4951, a drug administered as eye drops, alongside Aflibercept injections. These treatments are designed to inhibit vascular endothelial growth factor receptors, potentially reducing fluid leakage and swelling in the retina associated with DME.
This interventional study employs a randomized, parallel-group design with quadruple masking, meaning participants, care providers, investigators, and outcomes assessors are blinded to the treatment allocations. The primary purpose of the study is treatment-focused.
The study began on October 31, 2023, with primary completion and estimated completion dates yet to be announced. The latest update was submitted on July 28, 2025, indicating ongoing progress.
For investors, the successful development of KHK4951 could enhance Kyowa Kirin’s market position, potentially boosting stock performance and investor confidence. As the market for DME treatments is competitive, advancements in this study could differentiate Kyowa Kirin from its competitors.
The study is currently recruiting, with further details available on the ClinicalTrials portal.